PTJ
AUPH icon

Paul Tudor Jones’s Aurinia Pharmaceuticals AUPH Stock Holding History

Paul Tudor Jones’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-23,300
Closed -$345K – 3538
2026
Q1 		$345K Hold
23,300
– – ﹤0.01% 3057
2025
Q4 		$372K Buy
+23,300
New +$330K ﹤0.01% 2905

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Paul Tudor Jones's AUPH Position: Q2 2026 in Review

Paul Tudor Jones sold out of Aurinia Pharmaceuticals (AUPH) in Q2 2026, closing a stake of 51,568 shares — an estimated $764K sold.

Paul Tudor Jones first reported a position in AUPH in Q3 2021 and held it in 10 quarters. The position peaked at $1.16M in Q1 2023. 279 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

  • Paul Tudor Jones reported no remaining Aurinia Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Paul Tudor Jones sold 51,568 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $764K.
  • Paul Tudor Jones first reported a position in Aurinia Pharmaceuticals in Q3 2021 and held it in 10 quarters.
  • Paul Tudor Jones's Aurinia Pharmaceuticals position peaked at $1.16M in Q1 2023.
  • 279 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.